Related Experiment Videos
Serum human chorionic gonadotropin regression pattern in persistent trophoblastic disease during chemotherapy
R Lertkhachonsuk1, S Limpongsanurak
1Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
|September 1, 2001
Summary
The regression pattern of serum beta-hCG in persistent trophoblastic disease differs significantly between chemotherapy-sensitive and resistant groups. This difference is evident from week 3 to 7, aiding in early treatment response prediction.
Area of Science:
- Gynecology
- Oncology
- Reproductive Endocrinology
Background:
- Persistent trophoblastic disease (PTD) requires effective chemotherapy regimens.
- Monitoring serum beta-human chorionic gonadotropin (beta-hCG) is crucial for treatment assessment.
- Understanding beta-hCG regression patterns can predict chemotherapy response.
Purpose of the Study:
- To identify the regression pattern of serum beta-hCG in PTD patients undergoing chemotherapy.
- To differentiate beta-hCG reduction rates between chemo-sensitive and chemo-resistant PTD cases.
Main Methods:
- Retrospective analysis of 72 PTD patients receiving single-agent chemotherapy (1985-1998).
- Actinomycin-D was the primary first-line treatment for most patients.
- Serum beta-hCG levels were monitored to assess regression patterns and treatment response.
Main Results:
- 88.9% of patients responded to first-line chemotherapy; 11.1% were resistant.
- Significant differences in beta-hCG reduction rates were observed between the third and seventh week of chemotherapy.
- Initial beta-hCG levels did not significantly differ between chemo-sensitive and chemo-resistant groups.
Conclusions:
- The rate of beta-hCG decline effectively distinguishes between chemo-sensitive and chemo-resistant PTD.
- Monitoring beta-hCG reduction from week 3 to 7 post-chemotherapy initiation aids in early response prediction.
- This finding supports timely adjustments to chemotherapy regimens for PTD management.